**Futuristic Trends in the field of Recombinant DNA Technology to improve Human Life**

Poonam Verma1Priyanshu Sao2\*, Sontee Jangde3, N Kumar Swamy4

1Assistant Professor, School of Science, ISBM University, Chhura, Gariyaband, Chhattisgarh 493996

2Research Scholar, School of Science, ISBM University, Chhura, Gariyaband, Chhattisgarh 493996

3Research Assistance ICMR, NIMR, Raipur, Chhattisgarh, 49366

4Dean, School of Science, ISBM University, Chhura, Gariyaband, Chhattisgarh 493996

Corresponding Author: helloprishu@gmail.com

Mobile-+91-6263883851

**Abstract**

Recombinant DNA technology has significantly advanced human life by enabling the production of essential proteins for dietary needs and health issues. This technology has multidisciplinary applications, such as improving food resources, enhancing health, and fending against negative environmental repercussions. Agriculture uses genetically modified plants because they have superior survival rates, increased product output, and improved resistance to hazardous agents. Gene therapy and genetic changes are employed for bioremediation and the treatment of major illnesses, and recombinant medications are increasingly routinely used. The importance of recombinant DNA technology in daily life is evident due to its wide range of applications and potential applications.

**Keywords:** Health problems, Dietary purpose, Essential proteins, DNA technology, Recombinant, Application, Human life, Treating and Therapy.

**1. Introduction**

Food insecurity, health challenges, and environmental concerns all have a substantial influence on human life. Human life depends on food and health, and the growing global population wants safe, inexpensive food. Each year, considerable numbers of people die as a result of health problems such cancer, diabetes, AIDS/HIV, TB, and malaria. Despite efforts, Global food supply falls short of human needs, and third-world countries' health facilities are subpar. Industrial waste may now combine with water, causing environmental contamination and harming aquatic and marine life and humans indirectly. Addressing these issues requires modern technologies to improve living conditions and reduce the impact of these issues on our planet [1].

Modern techniques and methods like molecular cloning and transformation are used in genetic engineering to address difficulties with agriculture, human health, and the environment. This method takes less time and produces more trustworthy results. Genetic engineering, in contrast to conventional breeding, transforms the target by biolistic and *Agrobacterium*-mediated transformation to add a tiny block of desired genes. Plant genomes can be modified using methods like gene targeting depending on recombination, site-specific alteration caused by nucleases, integration caused by recombinases, and mutagenesis caused by oligonucleotides.

By creating novel vaccinations and medications, recombinant DNA technology is significantly enhancing health conditions. Additionally, the therapy approaches are enhanced. Through creating novel therapy strategies, monitoring tools, and diagnostic kits. The creation of novel mutant experimental mouse strains for scientific study and the genetic engineering of bacteria to produce synthesised insulin for humans and erythropoietin are two of the most well-known examples of using genetic engineering in the field of health [3]. Similar approaches, include turning trash into biofuels and bioethanol [4–7], getting rid of harmful materials like spilt oil and carbon atoms, and finding poisons like arsenic in water for consumption, have been utilised to solve environmental issues. The genetically modified bacteria can also be used for bioremediation process and biomining.

The development of recombinant DNA technology transformed biology and profoundly altered medical genetics and biomedicine. It made it possible to create therapeutic items by altering microbial, animal, and plant life to produce beneficial compounds for treating illnesses. The majority of biotechnology medicines are recombinant, and they are essential in the fight against fatal human illnesses. In 1997, the FDA authorised more recombinant medications for anaemia, AIDS, malignancies, hereditary conditions, Human growth hormone deficiency, multiple sclerosis, diphtheria, genital warts, Hepatitis B and C, and diabetic foot ulcers than in all prior years combined. For overcome these difficulties, advanced techniques like site-specific integration and controlled gene expression are essential [8-10]. Challenges in plant biotechnology include tanscriptional parameter of endogenous genes, effective new locations, and precise transgene expression control, requiring further development for successful application [11].

Human life is in risk from a variety of factors, such as food shortages that lead to environmental issues brought on by increased industrialization and development, many fatal illnesses, starvation, and many other things. Genetic engineering has taken the role of traditional methods because it has a higher possibility of success. The key challenges people confront were detailed in the current review, along with possible solutions including recombinant DNA technology. In keeping with this, we have outlined the genetic engineering constraints as well as potential future avenues for researchers to get beyond these restrictions by altering the genetic engineering techniques now being used.

**2. Recombinant DNA Technology**

In recombinant DNA technology, genetic material outside of an organism is changed to produce improved and desirable features of living things or the things they produce. This method entails inserting DNA fragments with acceptable gene sequences utilising the appropriate vector, from a variety of sources [12]. Several new genes and regulatory elements can be added to a genome, or existing genes and regulatory elements can be recombined, to change its composition lessen or stop the production of native genes [13]. Enzymes are employed to cleave DNA into distinct fragments, which are subsequently linked via DNA ligase enzyme to fix a specific gene in the vector. Restrictions endonucleases are utilised for particular target sequence DNA locations. The vector is then delivered to the host organism, which is later grown to produce a lot of replicas of the DNA insert fragment in culture. Then, clones that have the correct Picked out and retrieved DNA fragments [11]. Stanford University and University of California San Francisco developed the first recombinant DNA (rDNA) molecules in 1973 researchers Paul Berg, Herbert Boyer, Annie Chang, and Stanley Cohen. At "The Asilomar Conference" in 1975, rDNA technology regulations and safe application were discussed. The use It took longer than expected to develop Recombinant DNA to facilitate agricultural and medical achievements because of unexpected challenges and obstacles attaining the required results, which was contradictory to the desires of researchers at the time of Asilomar. But since the beginning of the 1980s, a wide range of items have been developed to improve health, including hormones, vaccines, drugs, and diagnostic instruments [13].

Recombinant DNA technology offers a quick way to assess the genetic makeup of the alterations made to eukaryote gene by the incorporation of copied insulin genes into a simian viral fragment [3]. Similar to this, a vector called adenoviral that encodes endostain mammalian secretory form reduced the development of tumours due to its antiangiogenic characteristics. The antiangiogenic effect of Dl1520 can be increased by preventing Ad-Endo replication [14]. Specific gene destruction has been used in different hosts to produce anticancer drugs that resembled their production pathways structurally [15].

Recombinant DNA techniques have been used to create therapeutic proteins with longer half-lives that contain glycosylation site sequences. Researchers have created a novel chimeric gene that combines HCG and FSH subunit coding sequences. Researchers have also developed vector and a vector combination for treatment with genes and genetic modification. Currently, viral vectors are often used in therapeutic contexts and may be bought [16].

With applications in the treatment of serious illnesses including cancer, immunisation, and protein transduction, viruses are modified for medical use. Clinical-grade viral vectors are now easier to get because to improvements in manufacturing technology. Retroviral vectors are becoming less used because of their negative side effects, although they efficiently transmit genes. When administered directly into tissues, especially muscles, the most basic nonviral gene delivery technique, employing "naked" DNA, results in large gene expression levels with little adverse effects [17-19].

A P1 vector was designed to electroporate the recombinant DNA into E. coli and generate a library of 15,000 clones with an average insert size of 130-150 kb. It is possible to map and analyse complicated genomes with this PAC cloning technique. pWSK29, pWKS30, pWSK129, and pWKS130 are examples of low copy number vectors that may be utilised for run-off transcription, complementation analysis, and unidirectional deletions. The technique of recombinant DNA has several uses, including genome mapping, analysis, and gene editing. Figure 1 provides an overview of a wide variety of recombinant DNA technology uses. [20-21].

Recombinant DNA Technology

Genetically engineered goods Fruits GM produce GM plants GM organisms GM creatures

Therapeutic items Vaccines hormonal growth Antibodies Vectors reconstituted protein Anticancer drugs

Energy applications Biohydrogen Bioethanol Biomethanol Biobutanol

Diagnosis Gene therapy CRISPR Monitoring devices Therapeutic strategies

**Figure 1: An example of the many uses for recombinant DNA technology.**

**3. Present Research Development**

Recombinant DNA technology is a rapidly expanding subject, and scientists from all over the world are creating novel techniques, tools, and modified goods for use in a variety of fields, encompassing the environment, health, and agriculture. An efficient and fast-acting recombinant insulin is Lispro (Humalog), is superior to conventional human insulin [3]. Like this, epoetin alpha is a fresh, well-known protein recombinant that may be used to effectively cure anaemia [22]. Children who are unable to produce adequate hGH on their own can be effectively treated with recombinant hGH. The Food and Drug Administration's authorization of clinical studies for a recombinant version of the cytokines myeloid precursor inhibitory factor-1 (MPIF-1) is a success to recognise this technology. It can mimic immunologically important cell division, which might lessen the side effects of anticancer drugs [23, 24]. The most recent advancements in the field of recombinant DNA technology are outlined in the section that follows.

CRISPR, a more recent advancement in recombinant DNA technology, has provided answers to a number of issues in several animals. This technique may be used to specifically target and eliminate human cell gene copies. By activating, inhibiting, elaborating, and removing genes from plants, mice, rats, zebrafish, fruit-fly yeast, nematodes, and human cells, the method's efficacy was demonstrated. With CRISPR, mouse models may be used for the study of human diseases. Individual gene studies are made much faster, and by changing a number of genes in cells, the study of gene relationships is made easier [25].

The CRISPR system in the H. hispanica genome is extremely adaptable to nonlytic viruses. The associated Cas operon codes for the interrupting Cas3 nucleases as well as other Cas proteins. A strain must be developed to prime CRISPR for the production of fresh spacers and priming crRNAs. The CRISPR-cas system needs to introduce more spacers to its locus in order to produce adaptive immunity [26]. The breakdown of foreign DNA and RNA is a controlled, sequence-specific mechanism. The host system is able to maintain knowledge of the intrusive's genetic information by integrating a photo-spacer into the CRISPR mechanism [27].

Cas9t (a gene editing tool) is one example of a DNA endonuclease that uses RNA molecules to detect specific targets [28]. A Class 2 CRISPRC as mechanism with just one protein as an effector can be employed for genome editing techniques. The recruiting of histone modifying enzymes, the start of transcription, the localization of fluorescent protein labels, and transcriptional repression all depend on dead Cas9 [29]. Targeting the genes involved in the isolation procedure for homozygous gene knockouts using CRISPR-induced mutations. This kind of critical gene analysis permits the investigation of "the potential antimicrobial targets" [30]. Natural CRISPR-cas the immune system has been utilised to produce strains that are resistant to numerous disruptive virus types [31].

The CRISPR-Cas system, which consists of a CRISPR array with short repeating elements and spacers, is the only adaptive immune system seen in prokaryotes. The array is flanked by cas genes that encode Cas proteins and is preceded by an AT-rich leader sequence. The cas1 and cas2 catalases encourage the synthesis of new spacers in Escherichia coli through complex formation. Since the target sequence requires interference and acquisition, the photo-spacer adjacent pattern (PAM) was deliberately chosen. The system inhibits self-targeting during the last stages of immunisation after CRISPR array transcription, which causes memory of the invader's sequence to begin to develop [32–34]. The CRISPR loci in Sulfolobus species include several spacers, which largely resemble conjugative plasmids. Active viral DNA replication has an impact on spacer acquisition, and DNA breaks at replication forks function as a catalyst. In complex biological systems, the CRISPR-Cas system has a special function that improves immune stability and stability [35].

Chimeric nucleases, like nucleases with transcription activator- like effector nu (TALENs) and zinc-finger structures (ZFNs), are made up of preprogrammed sequence-specific DNA-binding modules coupled to a not specific DNA cleavage domain. The therapeutic potential of ZFNs and TALENs is more specific and targeted [25, 36, 37]. There has also been development of a recombinant protein called called fibroblast growth factor (FGF-1), which promotes the development of new blood vessels in the myocardium. The heart's blood flow is increased when it is injected (via biological bypass) into an individual's myocardium. Derma-Graft and Apligraf, two FDA-approved medicines that function as recombined skin replacers and have been approved for the treatment of leg ulcers, can be used to successfully cure diabetic ulcers [38–40].

Since the manufacture of insulin from E. coli is now possible thanks to recombinant DNA technology, many different animals, including cattle and pigs, can now generate the hormone. However, immunological responses have resulted from this. Recombinant insulin made from humans is more suitable for medicinal requirements since it is not as immunogenic and more cheap. Human growth hormone was the first protein generated by tobacco plants. Modified microbial strains are used in the creation of new drugs and enhanced protein synthesis techniques thanks to recombinant DNA technology.

The advancement of molecular medicine, especially based on proteins, has serious issues with recombinant DNA procedures and the biological processes of the cells that work to produce compounds that are medically relevant. To address these issues, there is an urgent need to boost both the quantity and calibre of drugs based on molecular phenomena. Cell factories are considered to be vital in the development of recombinant DNA technologies, but these need to be researched in more depth and complexity since the needs cannot be provided by conventional factories [42].

Similar to this, an oncolytic adenovirus that imitates breast cancer was developed using vascular growth factor and Notch transmission. A tool for the antagonist's expression that is selective. By preventing tumour angiogenesis, this medication also has anticancer properties. This causes a significant change in both the total number of vessels in the body and the perfused vessels, showing increased efficiency against the effects of the vascular system and tumours [13].

In an effort to generate vaccines, the influenza virus's genome has been modified using recombinant DNA technology. The foundation of the changes is the design of vectors mediating the the expression of foreign genes. In actuality, the influenza virus's NS gene was changed by a foreign gene, frequently the chloramphenicol acetyltransferase gene.The previously recombined RNA is generated and condensed into viral particles following transfected with pure influenza A virus and helper virus. It has been established that the influenza A virus's 5 and 3 terminal nucleotides are enough to create signals for RNA transcription, RNA replication, and RNA packaging into influenza viruses [15].

The pathways for producing several vaccines and medications, among other things, are improved by the previously mentioned new manufacturing procedures. The physiology of a cell and the environment it is placed in both have an impact on the creation of high-quality proteins. Stress causes a cell to express proteins later, which in some circumstances may also encourage the production. Therefore, new developments are required for improved and more secure genetic and metabolic production. Microorganisms are thought to be the best possible hosts for the manufacture of molecular medicines. These cells' less robust defences make it possible for foreign genes to be assimilated, and expression may be easily controlled.

When utilised as hosts, microbial systems provide less sophisticated machinery than do plant and mammalian cells, which ultimately enhances the efficiency and standard of protein synthesis. Less common strains of bacteria and yeast have also showed promise as cellular factories for the synthesis of recombinant molecular therapies. However, the use of widely distributed microbial organisms, such as yeasts and bacteria, is promising. When this cellular factories of microorganisms are introduced into the medication production process, the demand for pharmaceuticals will increase and the requirement for quality will be addressed with better outcomes pharmaceutical manufacturing processes (Table 1) [41, 45, 46].

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Technique | Process | hang over (bp) | Scar (bp) | Comments | Examples of Implementation |
| BioBricks | Restriction endonuclease of type IIP | 8 | 8 | Sequentially assembles small numbers of sequences | Construction of a functional gene expressing enhanced cyan fluorescent protein |
| BglBricks | Type IIP restriction endonuclease | 6 | 6 | Uses a highly efficient and commonly used restriction endonuclease, the recognition sequences of which are not blocked by the most common DNA methylases | Construction of constitutively active gene-expression devices and chimeric, multidomain protein fusions |
| Pairwise selection | Type IIS restriction endonuclease | 65 | 4 | Attachment tags promote antibiotic resistance markers in fragments using a rapid liquid culture system. | Assembly of a 91 kb fragment from 1-2 kb fragments |
| GoldenGate | Type IIS restriction endonuclease | 4 | 0 | One-step assembly of 2-3 fragments |  |
| Overlapping PCR | Overlap | 0 | 0 | Uses overlapping primers for the PCR amplification of 1–3 kb-long fragments | Usually used for 1–3 kb-long fragments, for example, for gene cassette construction |
| CPEC | Overlap | 20–75 | 0 | Single polymerase assembly of multiple inserts in one-step in vitro vector assembly reaction. | One-step assembly of four 0.17–3.2 kb-long PCR fragments |
| Gateway | Overlap | 20 | 0 | Utilizes specific recombinase for small-scale processing. | assembly One-step assembly of three 0.8–2.3 kb-long fragments |

**4. Applications of Recombinant DNA Technology**

**4.1. Food and agricultural.**

Numerous uses of feasible to make unique enzymes that are suitable for specific food processing settings because to recombinant DNA technology. Due to their specialised functions and uses in the food industry, several vital enzymes, such as lipases, or, and amylases, are accessible for the specific producers.The creation of new microbial strains is yet another great achievement made feasible by recombinant DNA technology. Through targeted engineering, several strains of microbes have been developed that can produce enzymes, particularly proteases. To reduce their ability to create dangerous chemicals, several fungal strains have undergone changes [47]. The best instruments for eradicating germs in the food sector are lysozymes. They avoid colonisation of microscopic creatures. Fruits, vegetables, cheese, and meat may all be preserved with it since it extends the shelf life of these foods. Lysozyme immobilised in polyvinyl alcohol films and cellulose can be used to suppress food-spoileding germs. Fish skin gelatin gels that have been impregnated with lysozyme have longer shelf lives and are less likely to deteriorate [48–50]. It is possible to hydrolyze the exopolysaccharides of Staphylococcus and E. coli by using the T7-engineered DspB. The capacity of DspB to reduce bacterial population [50].

Biofilms related to the food business can be removed using the combined action of proteases that contain serine and amylases [51]. Yersinia enterocolitica, Campylobacter jejuni, L. monocytogenes, S. aureus, Salmonella infantis, Clostridium perfringens, B. cereus, along a number of other food-rotting bacteria are all susceptible to glucose oxidase's inhibitory effects. In the food industry, it is recognised as one of the most important enzymes for removing a range of pathogenic organisms from foods [50].

The first plant recently created recombinant protein molecules that are utilised as medications, and many more are on the road to being utilised to carry out further synthesis of analogous medically important proteins [52]. Various plant species have been employed to produce a wide variety of recombinant proteins for usage as enzymes in various sectors.

The nutrition-related proteins found in milk and novel polymeric proteins utilised in businesses and the medical area are two of the most commonly employed proteins in research [52]. With the advancement of HBV vaccine production in plants, the concept of oral immunisation utilising plants that are consumable has gained popularity. Plants have created a number of medicinal protein products, such as casein and lysozyme for improving newborn health as well as polymeric protein for replacement of tissues and surgery. Furthermore, human collagen can be produced by genetically altering tobacco plants.

The synthesis of exceptionally high producing molecular proteins is one of the main goals being considered in the field of the technology of recombinant DNA [52]. Conventional breeding and quantitative trade locus (QTL) research allowed for the detection of a particular strain of rice called PSTOL1 (phosphorus starvation tolerance1) that has protein kinase, which assists in promoting root growth in the early stages and tolerates phosphorus shortage [53]. When this enzyme is overexpressed, roots in phosphorus-deficient soil are able to absorb nutrients in appropriate quantities, improving grain yield [54]. The phylogeny and the development of plants are greatly influenced by the chloroplast genome sequences. Rpl22 is thought to have been moved from the chloroplast to the nuclear genomes.

Proteins are moved from the cytosolic to the chloroplast with the help of a peptide that is contained in this gene. It has been shown that a number of essential genes deleted from the chloroplast migrate into the nucleus and prevent anomalies in photosynthesis along with other vital processes, with the exception of ycf1 and ycf2. Trans-genesis via chloroplast is thought to be durable since nuclear transgenic plants suffer with decreasing activity and transgene migration through pollen. Transgenes have been integrated into the chloroplast genome in about ten thousand copies [55–57]. Although not under cellular control, heterologous regulatory sequences are necessary for transgene expression. Success has been discovered in the engineering of T7gene10 against salt stress, although with a decreased expression rate into nongreen tissues. The insertion of the -tmt genes into the genome of the chloroplast causes the inner chloroplast layer to form in layers. Lycopene is converted more readily to provitamin A when lycopene-cyclase genes are inserted into the tomato plastid genome [57, 58].

To find genes specific to an organ or tissue, gene expression profiles might be employed. Full-length cDNAs are the main resources for gene expression profiling. A 44 K Agilent Oligonucleotide microarray is used to investigate the transcriptome of rice grown in the field. The expression of genes variation and transcriptome changes may be predicted using transcriptomic data and meteorological information. These methods and projections can help boost agricultural productivity and improve crops' resistance to pathogenic or environmental problems.

In rice, the WRKY45 gene, which is activated by the plant promoter benzothiadiazole and promotes the innate immune system of the plant, can boost immunity against bacterial and fungal infections.To create grains that are larger in size, the qSW5 gene can be introduced. qSH1 prevents the formation of the separation layer, which stops seeds from breaking. The kala4 gene is responsible for the distinct black colour of rice, for instance, which makes it robust to disease attack [59, 60]. Genetic modification is necessary to enable the gene-by-gene implementation of well-known traits. It makes more of an organism's genes available for access.

Many plants are being developed with advantageous features, such as resistance to the herbicides glyphosate, resistance to insects, resistance to drought, resistance to diseases, and salt tolerance. These plants include potatoes, beans, eggplant, sweet potato, squash, and others.

**4.2. Diseases and Health**

There are several applications for recombinant DNA technology in the treatment of disease and improvement of physical health. The important advances in recombinant DNA technology for the enhancement of human health are described in the sections below: Enhancements to nutritional flexibility, ripening, and nitrogen uptake have also been made [61].

**(4.2.1). Gene Therapy**

Gene therapy is a cutting-edge technique with therapeutic potential in healthcare.The very first significant report in the field of the use of genes to cure a genetic ailment [62, 63] presented a more certain path towards curing the most fatal genetic conditions. Adenosine deaminase-deficiency (ADA-SCID), the most common immunodeficiency, responds favourably to treatment in this way. When this technique was first developed, it was difficult to maintain individuals receiving gene therapy who are taking PEG-ADA, and it was difficult to target gene transfer to T-lymphocytes, which led to poor outcomes [64, 65]. Later, however, targeted myeloablative chemotherapy and improved gene transfer techniques on haematopoietic stem cells (HSCs) conditioning regimen led to effective outcomes [66].

The expression of certain genes by lentiviral vectors based on HIV-1 has the potential to cause X-linked illness and adrenoleukodystrophy (X-ALD) [67]. The expression of the XALD protein shows that real HSCs' genes were properly corrected. Lentiviral vectors were utilised to successfully treat genetic human diseases for the first time [68]. Immunotherapy was utilised to treat metastatic melanoma in 2006 by enhancing the expression of a specific protein. This achievement in the health sciences opens up new avenues for the development of immunotherapy as a severe life-threatening illness treatment [69].

A retrovirus that encodes a T-cell receptor was utilised to create blood levels of cells specifically designed for cancer detection in two individuals, which resulted in the up to a year following the injection, fewer metastatic melanoma lesions were seen. Later, this method was used to treat patients with metastatic synovial cell cancer [70]. In order to treat chronic lymphocytic leukaemia, CARs that are selective towards the B-cell antigen CD19 were created using genetically altered autologous T-cells. Selective growth is applied to genetically engineered cells to treat conditions like SCID-X1 and ADASCID due to in vivo selection supplied by the disease pathogenesis, despite just a small number of progenitors being repaired. The possibility for combining gene and pharmacological treatment underlined lately in a study intended to provide human HSCs with chemoprotection following treatment with alkylating agents for glioblastoma [71].

A focused technique involves transferring genes to a small amount of cells in atomically specified regions that may be therapeutically advantageous. It has demonstrated remarkable results for fatal autosomal dominant dystrophies such Leber congenital amaurosis (LCA) and congenital blindness. A Swiss-German phase I/II clinical research on gene therapy for the treatment of chronic granulomatous disease was successful in April 2006 [72]. Two-thirds of the patients who received retrovirally transduced mobilised CD34+ cells extracted from peripheral blood exhibited obvious improvement from the therapy. Following treatment, methylation of the viral promoter silenced the transgene, which exacerbated the condition and ultimately led to the patient's death [73].

Gene therapy has been used to treat a wide range of cancers, including haematological malignancies, paediatric tumours, lung, gynaecological, cutaneous, urological, neurological, and gastrointestinal tumours. Different approaches have been tried to treat many forms of cancer, including the insertion of tumour suppressor genes into immunotherapy, oncolytic virotherapy, and gene guided enzyme prodrug treatment. Cancer treatment strategies heavily rely on the tumour suppressor gene p53, which is frequently inherited. P53 gene transfer is used in conjunction with radiation or chemotherapy in some of the techniques. vaccination using host cells modified to express cancer antigens, vaccination using modified viral vectors for expressing tumour antigens, and vaccination using tumour cells produced to generate immunostimulatory chemicals are the three most significant approaches now being used [19].

Ad5/35-EGFP, a novel fibre chimeric oncolytic adenovirus vector, provides an effective new anticancer agent for the more effective treatment of hepatocellular carcinoma. The correct assaying of these vectors demonstrated their importance for improving transduction, and more viral offspring were generated in HCC. While maintaining the normal cells' cytotoxicity resistance, On in vitro HCC cells, more transgenic expression was produced, and the anticancer effect was also enhanced. Using this technique also prevented the formation of tumours [74]. In recent years, cancer gene therapy has evolved and shown an increase in effectiveness [75].

A prominent medical research technique is the use of gene therapy to treat cardiovascular problems. In the realm of cardiovascular medicine, gene therapy will create new opportunities for medicinal angiogenesis, which myocardium protection, regrowth, and repair, avoiding restenosis following an angioplasty prevention of bypasses transplant failure, and associated risk management. WASP is a protein that controls the cytoskeleton, and mutations in the gene that codes for it lead to Wiskott-Aldrich Syndrome (inherited immunodeficiency). Autologous HSPCs that have received ex vivo gene therapy are administered intravenously to treat the disease when matching donors are not accessible for transplantation of stem cells [76].

Through gene-engineered T-cell adoptive transfer as immunotherapy, metastatic cancer can be retreated. This therapy primarily focuses on accurate targeting of tumour antigens and their associated the vessels, as well as efficient utilisation of genetic engineering for reactivating T-cells prior to patient transfer [77]. T-cell survival and migration are suppressed by the microenvironment of cancer cells, which frequently renders them nearly "invisible" to the immune system. T-cell genetic engineering is the solution to these issues. The genes that identify cancer-specific antigens, offer protection against immunosuppression, increase lifespan, and encourage migration can be recombined to modify the T cells of cancer patients to tumours [78].

The fusion of the gene Echinoderms microtubule-associated proteins like 4 (EML4) and anaplastic lymphoid kinase (ALK), which is resulting from an insertion on the chromosome's short arm, confers anaplastic lymphoma kinase (ALK) inhibitor sensitivity. Specific chromosomal rearrangements are brought about when the CRISPR/Cas9 system is delivered through a vial to somatic cells of mature animals [79]. Wnt signalling is one of the primary oncogenic routes in many cancers. Targeting the Wnt system is an interesting therapeutic approach for treating cancer, because LGK974 potently reduces Wnt signalling and has high efficacy in mice tumour models and is well tolerated. High levels of LGK974 response are observed in cell lines from Cancer of the head and neck with functional loss Mutations in the Notch signalling pathway [80].

A codon optimized gene was created and copied into the influenza virus using the codon structure of the hemagglutinin gene the recombinant modified vaccinia virus Ankara (MVA). The ferret MVA-H7-Sh2 viral vector vaccine was found to be immunogenic because mock-vaccinated unprotected animals developed interstitial pneumonia and lost weight, whereas MVAH7-Sh2 immunisation shielded the animals from severe illness [81]. One of the most effective and significant treatments for head and neck cancer is viral gene therapy. Viral treatment first targeted the p53 gene function because it targets tumor-associated genes. Oncolytic viruses can kill cancer cells by replicating the virus and equipping themselves with therapeutic transgenes [82].

Cells that have the high The ABCA1 gene for density lipoprotein can become mutated into macrophages. Gene knockouts improve the capacity of cells to develop into macrophages and precisely target the targeted pathogens in embryonic stem cells. The allele substitutions in this condition will facilitate the study of mRNA transcription and stabilisation in macrophages are modified by protein coding alterations and regulatory variations. [83].

Seven of the designed and expressed antibodies including their derivatives were effective in completing the necessary phases in plant systems. To recognise Streptococcus variations, an oral pathogen that causes tooth decay, transgenic tobacco plants can be used to produce chimeric secretory IgA/G, commonly known as CaroRx. Antigen carcinoembryonic, an emotionally charged the monoclonal antibody T84.66 may be capable of effectively recognising a marker in epithelia malignancies.

An anti-HSV and anti-RSV full-length humanised IgG1 that is functional. Specifically, Chinese Hamster Ovary (CHO) and transgenic soybean cells, glycoprotein B has been produced as the herpes simplex virus (HSV)-2 recognising agent. When applied topically, antibodies from both sources have been demonstrated to stop the transmission of HSV-2 through the vagina in mice; if this were also true in people, it would be regarded as an effective and affordable method of preventing infections that are spread through sexual contact [86–88]. Based on the well-researched mouse lymphoma cell line 38C13's malignant B lymphocyte idiotype, scFv antibody 38C13 was created.

When mice were given the antibody, it caused the creation of anti-idiotype antibodies that could identify 38C13 cells, helping to protect the animals from the deadly challenge of being injected with lymphoma cells [89, 90]. Through this technique, distinct In particular, malignant B-cell surface indicators might be recognised by enzymes to be used as an effective therapy for non-Hodgkin lymphoma-like conditions in humans [61]. Human chorionic gonadotropin recognition is specific for a monoclonal antibody known as PIPP. Transgenesis and agroinfiltration in transiently transformed tobacco allowed for the generation of full-length monoclonal antibodies, as well as scFv and diabody derivatives [91].

In cells cultivated by LEYDIG, stimulated hCG can suppress the generation of testosterone, and in mice, who are used to measure hCG activity, uterine weight increase can be slowed. Antibodies can be used in the diagnosis and treatment of tumours [61].

**4.2.3: Research on Drug Metabolism.**

Examining the complex structure of enzymes that regulate medication metabolism is crucial for achieving the best therapeutic results. Using heterologous expression, which means that the genetic code for the enzyme is created in vitro or in vivo by the transfer of a gene, recent developments in recombinant DNA methods have contributed to its function [92, 93].

**4.2.4. Production of Recombinant Hormones and Vaccines.**

Recombinant vaccines outperform conventional vaccines in terms of effectiveness and specificity in comparison. Nasal transfer is a quick and effective way to fight mucosal diseases while also being painless and fearless way to transmit adenovirus vectors encoding pathogen antigens.

By expressing a transgene in the airway, this serves as a pharmacological vaccination that can create an anti-influenza state [74].

Through the use of recombinant DNA technology, human follicle-stimulating hormone (FSH) may now be produced in vitro. FSH is a very complicated heterodimeric protein that has been expressed in a particular cell line from eukaryotes. A success of recombinant DNA technology is the stimulation of follicular development in assisted reproductive therapy. Through the use of r-FSH, many patients are being treated. The most intriguing development was the effective recombination of r-FSH and luteinizing hormone (LH) to improve ovulation and pregnancy [94, 95].

**4.2.5. Chinese medicines**

Traditional Chinese Medications are a crucial component of complementary therapies and are very important for both diagnosing and treating health problems. These drugs are associated with theories that, in part, back up the fundamental tenets of gene therapy. These drugs may function as sources of gene therapies as well as co-administered drugs. The transgenic root system provides fantastic opportunities for the insertion of other genes in addition to the Ri plasmid With A. rhizogenes vector systems, it usually comes with modified genes to improve properties for particular uses. Cultures become an important resource resource for studying the biochemical properties and gene expression pattern of metabolic pathways. Turned cultures can clarify the key enzymes and intermediates used in the production of secondary metabolites [96, 97].

**4.2.6. Medically Significant Compounds in Berries**

The rolC gene has contributed to an improvement in strawberries' nutritional value. This gene elevates the amount of sugar andantioxidant performance. Anthocyanins must be glycosylated using the enzymes transferase and glycosyl-transferase. For enhancing the component of interest by genetic modification, Relevant nutrition-related genes include those for proanthocyanidin, l-ascorbate, flavonoid compounds polyphenols, and flavonoid, among other strawberry constituents.

The bHLH and FRUITE4 genes in raspberries regulate the anthocyanin content of the fruit, whereas ERubLRSQ072H02 is connected to flavonol. These genes have the ability to boost production and raise quality through precise transformation. All of the aforementioned substances have therapeutic benefits [98].

**4.3. Environment**

Genetic engineering may be used to address several environmental issues biologically the distribution. The Pseudomonas fluorescens strain known as HK44, among others, were initially used by the University of Tennessee and Oak Ridge National Laboratory for field bioremediation [99, 100]. The transformed strain had a promoter-linked transposon-based lux gene that produced bioluminescence. that led to increased naphthalene breakdown and a concomitant bioluminescent response [101, 102] as well as a naphthalene catabolic plasmid called pUTK21 [101]. Due to its bioluminescence signalling abilities, HK44 may be utilised as a technique for monitoring in situ bioremediation processes online in addition to serving as a reporter for naphthalene bioavailability and biodegradation [102]. Fibre optics and photon counting modules can be used to identify the presence of a bioluminescent signal [101].

**4.4. Development of Plant Resistance and Phytoremediation.**

The use of genetic engineering has been extensively used for the identification and absorption of contaminants in water for drinking and other samples. For instance, the garden plants Verbena, Torenia, and Petunia's ability to absorb Pi was changed by the insertion of the AtPHR1 gene. Effective phytoremediation in contaminated aquatic settings may be facilitated by AtPHR1 transgenic plants with improved Pi absorption capacity [103]. The binary vector pBinPLUS was modified to incorporate a segment of the AtPHR1 gene and an improved cauliflower mosaic. The 35S viral promoter. Petunia and Verbena were transformed using this plasmid known as pSPB1898 [105] and Agrobacterium tumefaciens [104]. Although AtPHR1 is successful in other plant species as Torenia, Petunia, and Verbena [103], overexpression of AtPHR1 may prevent the endogenous AtPHR1 counterpart from being modified post-transcriptionally.

Plant metabolism identifies its value in using them to remove toxins from the environment. Some of the compounds are not easily digested or broken down.

TNT only undergoes a partial digestion process, during which time the nitrogen interacts with the oxygen to produce lethal superoxide. In order to solve this problem, monodehydroascorbate reductase gene is knocked out, increasing plant tolerance to TNT. By using knockout engineering and adjusting enzyme activity, we can improve how plants react to dangerous metals. A method of improving tolerance to heavy metals through enzymatic activity attenuation was discovered by phytochelatin synthase, an enzyme that produces heavy metal-binding peptides [106].

Recombinant DNA technology has demonstrated its efficacy in eliminating particles of arsenic, which are regarded as severe pollutants in soil. PvACR3, an essential arsenite [As(III)] antiporter with improved arsenic tolerance, was expressed in Arabidopsis. In contrast to wild-type seeds, which frequently perish in the presence of higher-than-normal levels of arsenate [As(V)], PvACR3-modified plant seeds may germinate and thrive under these circumstances. Arsenic (As) is reduced by the enzyme as reductase, which is present in A. thaliana. Arsenic movement in root cells and phloem partner cells is constrained by phytochelatins. OsNramp5 and OsHMA3 are the carriers for cadmium (Cd) uptake and retention [107].

In influencing processes of growth and development in plants, brassino-steroid (BR) plays a key function. It works by starting a chain reaction of phosphorylation or the dephosphorylation [108]. Recent technological strategies for bioremediation, such as the the biosorption process Enhancing the environment is crucial for dendro-remediation phyto-stabilization, cyano-remediation, hyper-accumulation, bio-stimulation, my-coremediation and geno-remediation or inhibiting specific gene activity. However, it is important to ignore the challenges associated with applying the successful strategy [109].

**4.3.2. Energy Applications**

A variety of microorganisms, including cyanobacteria, aid in the synthesis of hydrogen, a sustainable energy source. The intended output is maintained by properly using the required enzymes, which are essential to the production of the product. But modern methods have been effective in increasing the amount of hydrogen generation in cyanobacteria and other biofuels [3, 4], including the use of metabolic engineering, cell-free technology, combined culture, genetic engineering, and adjustments to the nutritional and growth circumstances. While this energy source is commercialised, the environment will remain clean, which is impossible while utilising current energy sources that release CO2 and other dangerous pollutants [113].

The ability of cyanobacteria to convert CO2 into lower fuel components can also be improved. As a result, carbon-based energy sources will no longer cause environmental harm. Numerous common chemicals, especially energy transporters like short- and medium-chain alcohols, have shown promise using this approach [114].

Geobacter sulfurreducens' conductive biofilms are potential sources for bioelectronics, bioremediation, and renewable energy. The G. sulfurreducens genome's PilZ gene deletion rendered the biofilm more active than it would have been under wild-type conditions. For the strain where the gene GSU1240 was deleted, CL-1ln is given. Along with pili and exopolysaccharide synthesis, biofilm generation was improved. When biofilms were cultivated with electrode, In comparison to wild-type biofilms, the electron acceptor CL-1 produced bio films that were seven times more conductive. With this high fold conductivity, potential losses in microbial fuel cells were decreased by lowering the formal potential and reducing the charge transfer resistance at the biofilmanode surface. Lower losses led to an increase in potential energy [115].

**5. Current Obstacles and Prospects**

The predominant usage of microbial cells in manufacturing. Recombinant medicines are hampered by a variety of obstacles that make it difficult for them to produce functional proteins, but they are still making progress are overcome with changes to the biological systems. Common obstacles to be overcome include post-translational modifications, active cell stress responses, erratic proteolytic activity, limited dissolution, and resistance to gene induction. Protein synthesis becomes insufficient as a result of human genetic mutations, but this introduce genes that are foreign in order to fill in the spaces and restore levels to normal, this issue could be resolved. Escherichia coli serves as the biological basis for recombinant DNA technology, enabling manufacturers to operate in controlled environments to technically and economically construct the required molecules [41, 116].

By enabling the investigation and modification of yeast genes both in the test tube and in living yeast cells, recombinant DNA research holds considerable potential for improving our understanding of yeast biology. Most notably, the cloning of genes and DNA transformation utilising a number of specifically created selectable marker systems now make it feasible to go back to yeast. These developments in technology have made it feasible to control and examine yeast genetic material at both the molecular and conventional genetic levels. Recombinant DNA technology has been particularly effective in resolving biological problems where the organisation and structure of individual genes pose a fundamental challenge [117, 118].

Recombinant DNA technology is now developing quickly, which has significantly changed research fields and provided new, intriguing opportunities for studying biosynthetic processes via genetic manipulation. Actinomycetes are used in the production of medicines, including the alteration of biosynthetic pathways for the manufacture of novel drugs and certain useful compounds in the health sciences. These have been heavily taken into account when building recombinant medications since they produce a significant portion of biosynthetic chemicals. Their chemicals have shown to be highly efficient against a wide variety of bacteria and other dangerous microorganisms, which makes them more pertinent in clinical investigations. These chemicals also have shown immunosuppressive and anticancer effects [119].

Recombinant DNA technology is used in gene therapy to create DNA vaccines for various diseases and to prevent and correct genetic defects. Clinical trial DNA is largely employed to cure cancer. High transfection efficiency in gene delivery devices is the subject of research. The possibility of transfection for less invasive Research into cancer treatment using genes is ongoing. Renal fibrosis,haemophilia, renal transplantation, Alport syndrome, Gaucher disease,  and other disorders are also being investigated as potential candidates for gene therapy.

**6. Recommendations**

A key scientific development that has significantly improved human existence is recombinant DNA technology. Recently, it has created methods for treating diseases including cancer, genetic conditions, diabetes, and a variety of plant maladies, especially virus and fungal resistance. Recombinant DNA manufacturing has received high commendation for its involvement in phytoremediation as and microbial remediation of pollutants as well as for enhancing plant resistance to many harmful elements (drought, insects and salt).

It greatly enhanced not just people but also plants, bacteria, and other kinds of living things. In the interest of advancing recombinant DNA technology, it is occasionally necessary to overcome significant difficulties in the process of gene-level product enhancement.

Because the body refuses the gene modification, there are considerable issues with creating high-quality items, especially for the pharmaceutical business. Additionally, expanding a product isn't always a wise idea because several factors might militate against its success. Recombinant technology is helping to cure a variety of diseases that are difficult to treat normally, but the immune responses make it challenging to get satisfying results.

Numerous issues with genetic engineering approaches need to be overcome through more focused gene amplification that is compatible with the organism's DNA. Single-stranded DNA would be incorporated into the chromosome of bacteria by a RecA-dependent mechanism. This requires that the entering DNA and the bacterial chromosome have comparable sequences. It could be possible to make plasmid reconstruction and stable maintenance straightforward. When genetic information from one source is inserted into another, safety and biodiversity suffer. The development of genetically engineered goods and plants has a number of drawbacks.

As an illustration, it is obvious that plants that have undergone genetic modification may mate with wild plants, releasing its "engineered" DNA into the environment and endangering our biodiversity. There are also concerns that genetic engineering can be detrimental to health. To address these issues and the public's worries, further research in this field is thus required.

**References**

[1]. S. Kumar and A. Kumar, “Role of genetic engineering in agriculture,” Plant Archives, vol. 15, pp. 1–6, 2015.

[2]. T. Cardi and C. N. Stewart Jr., “Progress of targeted genome modification approaches in higher plants,” Plant Cell Reports, vol. 35, no. 7, pp. 1401–1416, 2016.

[3]. P. T. Lomedico, “Use of recombinant DNA technology to program eukaryotic cells to synthesize rat proinsulin: a rapid expression assay for cloned genes,” Proceedings of the National Academy of Sciences of the United States of America, vol. 79, no. 19, pp. 5798–5802, 1982.

[4]. M. W. Ullah, W. A. Khattak, M. Ul-Islam, S. Khan, and J. K. Park, “Encapsulated yeast cell-free system: a strategy for cost-effective and sustainable production of bio-ethanol in consecutive batches,” Biotechnology and Bioprocess Engineering, vol. 20, no. 3, pp. 561–575, 2015.

[5]. M. W. Ullah, W. A. Khattak, M. Ul-Islam, S. Khan, and J. K. Park, “Bio-ethanol production through simultaneous saccharification and fermentation using an encapsulated reconstituted cell-free enzyme system,” Biochemical Engineering Journal, vol. 91, pp. 110–119, 2014.

[6]. W. A. Khattak, M. Ul-Islam, M. W. Ullah, B. Yu, S. Khan, and J. K. Park, “Yeast cell-free enzyme system for bio-ethanol production at elevated temperatures,” Process Biochemistry, vol. 49, no. 3, pp. 357–364, 2014.

[7]. W. A. Khattak, M. W. Ullah, M. Ul-Islam et al., “Developmental strategies and regulation of cell-free enzyme system for ethanol production: a molecular prospective,” Applied Microbiology and Biotechnology, vol. 98, no. 23, pp. 9561–9578, 2014.

[8]. L. Galambos and J. L. Sturchio, “Pharmaceutical firms and the transition to biotechnology: a study in strategic innovation,” Business History Review, vol. 72, no. 2, pp. 250–278, 1998.

[9]. F. M. Steinberg and J. Raso, “Biotech pharmaceuticals and biotherapy: an overview,” Journal of Pharmacy and Pharmaceutical Science, vol. 1, no. 2, pp. 48–59, 1998.

[10]. W. Liu, J. S. Yuan, and C. N. Stewart Jr., “Advanced genetic tools for plant biotechnology,” Nature Reviews Genetics, vol. 14, no. 11, pp. 781–793, 2013.

[11]. M. Venter, “Synthetic promoters: genetic control through cis engineering,” Trends in Plant Science, vol. 12, no. 3, pp. 118–124, 2007.

[12]. A. Berk and S. L. Zipursky, Molecular Cell Biology, vol. 4, WH Freeman, New York, NY, USA, 2000.

[13]. M. Bazan-Peregrino, R. C. A. Sainson, R. C. Carlisle et al., “Combining virotherapy and angiotherapy for the treatment of breast cancer,” Cancer Gene Therapy, vol. 20, no. 8, pp. 461–468, 2013.

[14]. L.-X. Li, Y.-L. Zhang, L. Zhou et al., “Antitumor efficacy of a recombinant adenovirus encoding endostatin combined with an E1B55KD-deficient adenovirus in gastric cancer cells,” Journal of Translational Medicine, vol. 11, no. 1, article 257, 2013.

[15]. C. M´endez and J. A. Salas, “On the generation of novel anticancer drugs by recombinant DNA technology: the use of combinatorial biosynthesis to produce novel drugs,” Combinatorial Chemistry — High Throughput Screening, vol. 6, no. 6, pp. 513–526, 2003.

[16]. B. C. J. M. Fauser, B. M. J. L. Mannaerts, P. Devroey, A. Leader, I. Boime, and D. T. Baird, “Advances in recombinant DNA technology: corifollitropin alfa, a hybrid molecule with sustained follicle-stimulating activity and reduced injection frequency,” Human Reproduction Update, vol. 15, no. 3, pp. 309– 321, 2009.

[17]. O. Merten and B. Gaillet, “Viral vectors for gene therapy and gene modification approaches,” Biochemical Engineering Journal, vol. 108, pp. 98–115, 2016.

[18]. O.-W. Merten, M. Schweizer, P. Chahal, and A. A. Kamen, “Manufacturing of viral vectors for gene therapy: part I. Upstream processing,” Pharmaceutical Bioprocessing, vol. 2, no. 2, pp. 183–203, 2014.

[19]. S. L. Ginn, I. E. Alexander, M. L. Edelstein, M. R. Abedi, and J. Wixon, “Gene therapy clinical trials worldwide to 2012—an update,” Journal of Gene Medicine, vol. 15, no. 2, pp. 65–77, 2013.

[20]. A. Rivero-M¨uller, S. Laji´c, and I. Huhtaniemi, “Assisted large fragment insertion by Red/ET-recombination (ALFIRE)—an alternative and enhanced method for large fragment recombineering,” Nucleic Acids Research, vol. 35, no. 10, article e78, 2007.

[21]. L. E. Metzger IV and C. R. H. Raetz, “Purification and characterization of the lipid A disaccharide synthase (LpxB) from Escherichia coli, a peripheral membrane protein,” Biochemistry, vol. 48, no. 48, pp. 11559–11571, 2009.

[22]. E. A. Masson, J. E. Patmore, P. D. Brash et al., “Pregnancy outcome in Type 1 diabetes mellitus treated with insulin lispro (Humalog),” Diabetic Medicine, vol. 20, no. 1, pp. 46–50, 2003.

[23]. A. K. Patra, R. Mukhopadhyay, R. Mukhija, A. Krishnan, L. C. Garg, and A. K. Panda, “Optimization of inclusion body solubilization and renaturation of recombinant human growth hormone from Escherichia coil,” Protein Expression and Purification, vol. 18, no. 2, pp. 182–192, 2000.

[24]. D. C. Macallan, C. Baldwin, S. Mandalia et al., “Treatment of altered body composition in HIV-associated lipodystrophy: comparison of rosiglitazone, pravastatin, and recombinant human growth hormone,” HIV Clinical Trials, vol. 9, no. 4, pp. 254–268, 2008.

[25]. E. Pennisi, “The CRISPR craze,” Science, vol. 341, no. 6148, pp. 833–836, 2013.

[26]. R. Wang, M. Li, L. Gong, S. Hu, and H. Xiang, “DNA motifs determining the accuracy of repeat duplication during CRISPR adaptation in Haloarcula hispanica,” Nucleic Acids Research, vol. 44, no. 9, pp. 4266–4277, 2016.

[27]. S. Shmakov, O. O. Abudayyeh, K. S. Makarova et al., “Discovery and Functional Characterization of Diverse Class 2 CRISPRCas Systems,” Molecular Cell, vol. 60, no. 3, pp. 385–397, 2015.

[28]. G. Gasiunas and V. Siksnys, “RNA-dependent DNA endonuclease Cas9 of the CRISPR system: holy grail of genome editing?” Trends in Microbiology, vol. 21, no. 11, pp. 562–567, 2013.

[29]. P. Mohanraju, K. S. Makarova, B. Zetsche, F. Zhang, E. V. Koonin, and J. van der Oost, “Diverse evolutionary roots and mechanistic variations of the CRISPR-Cas systems,” Science, vol. 353, no. 6299, 2016.

[30]. V. K. Vyas, M. I. Barrasa, and G. R. Fink, “A Candida albicans CRISPR system permits genetic engineering of essential genes and gene families,” Science Advances, vol. 1, no. 3, Article ID e1500248, 2015.

[31]. A. P. Hynes, S. J. Labrie, and S. Moineau, “Programming native CRISPR arrays for the generation of targeted immunity,” mBio, vol. 7, no. 3, p. e00202-16, 2016.

[32]. F. Hille and E. Charpentier, “CRISPR-Cas: biology, mechanisms and relevance,”Philosophical Transactions of the Royal Society B: Biological Sciences, vol. 371, no. 1707, Article ID 20150496, 2016.

[33]. K. S. Makarova, Y. I. Wolf, O. S. Alkhnbashi et al., “An updated evolutionary classification of CRISPR-Cas systems,” Nature Reviews Microbiology, vol. 13, no. 11, pp. 722–736, 2015.

[34]. D. Rath, L. Amlinger, A. Rath, and M. Lundgren, “The CRISPRCas immune system: biology, mechanisms and applications,” Biochimie, vol. 117, pp. 119–128, 2015.

[35]. G. Liu, Q. She, and R. A. Garrett, “Diverse CRISPR-Cas responses and dramatic cellular DNA changes and cell death in pKEF9-conjugated Sulfolobus species,” Nucleic Acids Research, vol. 44, no. 9, pp. 4233–4242, 2016.

[36]. T. Gaj, C. A. Gersbach, and C. F. Barbas, “ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering,” Trends in Biotechnology, vol. 31, no. 7, pp. 397–405, 2013.

[37]. P. R. Blackburn, J. M. Campbell, K. J. Clark, and S. C. Ekker, “The CRISPR system—keeping zebrafish gene targeting fresh,” Zebrafish, vol. 10, no. 1, pp. 116–118, 2013.

[38]. G. D. Yancopoulos, S. Davis, N. W. Gale, J. S. Rudge, S. J. Wiegand, and J. Holash, “Vascular-specific growth factors and blood vessel formation,” Nature, vol. 407, no. 6801, pp. 242–248, 2000.

[39]. R. K. Jain, P. Au, J. Tam, D. G. Duda, and D. Fukumura, “Engineering vascularized tissue,” Nature Biotechnology, vol. 23, no. 7, pp. 821–823, 2005.

[40]. K. Naoto, F. Dai, G. Oliver, A. Patrick, S. S. Jeffrey, and K. J. Rakesh, “Tissue engineering: creation of long-lasting blood vessels,” Nature, vol. 428, pp. 138–139, 2004.

[41]. N. Ferrer-Miralles, J. Domingo-Esp´ın, J. Corchero, E. V´azquez, and A. Villaverde, “Microbial factories for recombinant pharmaceuticals,” Microbial Cell Factories, vol. 8, article 17, 2009.

[42]. M. Kamionka, “Engineering of therapeutic proteins production in Escherichia coli,” Current Pharmaceutical Biotechnology, vol. 12, no. 2, pp. 268–274, 2011.

[43]. S. Eriksson, “Enzymatic synthesis of nucleoside triphosphates,” in Nucleoside Triphosphates and their Analogs: Chemistry, Biotechnology, and Biological Applications, vol. 23, 2016.

[44]. D. J. Urban and B. L. Roth, “DREADDs (designer receptors exclusively activated by designer drugs): chemogenetic tools with therapeutic utility,” Annual Review of Pharmacology and Toxicology, vol. 55, pp. 399–417, 2015.

[45]. J. S. Tzartos, M. A. Friese, M. J. Craner et al., “Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis,” The American Journal of Pathology, vol. 172, no. 1, pp. 146–155, 2008.

[46]. K. Rabe, M. Lehrke, K. G. Parhofer, and U. C. Broedl, “Adipokines and insulin resistance,” MolecularMedicine, vol. 14, no. 11-12, pp. 741–751, 2008.

[47]. Z. S. Olempska-Beer, R. I. Merker, M. D. Ditto, and M. J. DiNovi, “Food-processing enzymes from recombinant microorganisms—a review,” Regulatory Toxicology and Pharmacology, vol. 45, no. 2, pp. 144–158, 2006.

[48]. Z.-X. Lian, Z.-S. Ma, J. Wei, and H. Liu, “Preparation and characterization of immobilized lysozyme and evaluation of its application in edible coatings,” Process Biochemistry, vol. 47, no. 2, pp. 201–208, 2012.

[49]. S. H. Bang, A. Jang, J. Yoon et al., “Evaluation of whole lysosomal enzymes directly immobilized on titanium (IV) oxide used in the development of antimicrobial agents,” Enzyme and Microbial Technology, vol. 49, no. 3, pp. 260–265, 2011.

[50]. B. Thallinger, E. N. Prasetyo, G. S. Nyanhongo, and G. M. Guebitz, “Antimicrobial enzymes: an emerging strategy to fight microbes and microbial biofilms,” Biotechnology Journal, vol. 8, no. 1, pp. 97–109, 2013.

[51]. C. E. Torres, G. Lenon, D. Craperi, R. Wilting, and A. Blanco, ´ “Enzymatic treatment for preventing biofilm formation in the paper industry,” Applied Microbiology and Biotechnology, vol. 92, no. 1, pp. 95–103, 2011.

[52]. J. K.-C. Ma, P. M. W. Drake, and P. Christou, “The production of recombinant pharmaceutical proteins in plants,” Nature Reviews Genetics, vol. 4, no. 10, pp. 794–805, 2003.

[53]. R. Gamuyao, J. H. Chin, J. Pariasca-Tanaka et al., “The protein kinase Pstol1 from traditional rice confers tolerance of phosphorus deficiency,” Nature, vol. 488, no. 7412, pp. 535–539, 2012.

[54]. K. Hiruma, N. Gerlach, S. Sacrist´an et al., “Root endophyte Colletotrichum tofieldiae confers plant fitness benefits that are phosphate status dependent,” Cell, vol. 165, no. 2, pp. 464–474, 2016.

[55]. S. Jin and H. Daniell, “The engineered chloroplast genome just got smarter,” Trends in Plant Science, vol. 20, no. 10, pp. 622–640, 2015.

[56]. D. J. Oldenburg and A. J. Bendich, “DNA maintenance in plastids and mitochondria of plants,” Frontiers in Plant Science, vol. 6, article 883, 2015.

[57]. D. Henry, L. Choun-Sea, Y. Ming, and C. Wan-Jung, “Chloroplast genomes: diversity, evolution, and applications in genetic engineering,” Genome Biology, vol. 17, article 134, 2016.

[58]. W. Apel and R. Bock, “Enhancement of carotenoid biosynthesis in transplastomic tomatoes by induced lycopene-to-provitamin A conversion,” Plant Physiology, vol. 151, no. 1, pp. 59–66, 2009.

[59]. T. Oikawa, H. Maeda, T. Oguchi et al., “The birth of a black rice gene and its local spread by introgression,” Plant Cell, vol. 27, no. 9, pp. 2401–2414, 2015.

[60]. Y. Oono, T. Yazawa, Y. Kawahara et al., “Genome-wide transcriptome analysis reveals that cadmium stress signaling controls the expression of genes in drought stress signal pathways in rice,” PLoS ONE, vol. 9, no. 5, Article ID e96946, 2014.

[61]. European Commission, Restrictions of geographical scope of GMO applications/authorisations: Member States demands and outcomes, 2015, http://ec.europa.eu/food/plant/gmo/authorisation.

[62]. M. Cavazzana-Calvo, S. Hacein-Bey, G. De Saint Basile et al., “Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease,” Science, vol. 288, no. 5466, pp. 669–672, 2000.

[63]. S. Hacein-Bey-Abina, F. Le Deist, F. Carlier et al., “Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy,”The New England Journal of Medicine, vol. 346, no. 16, pp. 1185–1193, 2002.

[64]. S. J. Howe, M. R. Mansour, K. Schwarzwaelder et al., “Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients,” Journal of Clinical Investigation, vol. 118, no. 9, pp. 3143–3150, 2008.

[65]. R. M. Blaese, K. W. Culver, A. D. Miller et al., “T lymphocytedirected gene therapy for ADA-SCID: initial trial results after 4 years,” Science, vol. 270, no. 5235, pp. 475–480, 1995.

[66]. A. Aiuti, S. Vai, A. Mortellaro et al., “Immune reconstitution in ADA-SCID after PBL gene therapy and discontinuation of enzyme replacement,” Nature Medicine, vol. 8, no. 5, pp. 423– 425, 2002.

[67]. N. Cartier, S. Hacein-Bey-Abina, C. C. Bartholomae et al., “Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy,” Science, vol. 326, no. 5954, pp. 818–823, 2009.

[68]. E. Montini, A. Biffi, A. Calabria et al., “Integration site analysis in a clinical trial of lentiviral vector based haematopoietic stem cell gene therapy for meatchromatic leukodystrophy,” Human Gene Therapy, vol. 23, article A13, 2012.

[69]. R. A. Morgan, M. E. Dudley, J. R. Wunderlich et al., “Cancer regression in patients after transfer of genetically engineered lymphocytes,” Science, vol. 314, no. 5796, pp. 126–129, 2006.

[70]. P. F. Robbins, R. A. Morgan, S. A. Feldman et al., “Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1,” Journal of Clinical Oncology, vol. 29, no. 7, pp. 917–924, 2011.

[71]. J. E. Adair, B. C. Beard, G. D. Trobridge et al., “Extended survival of glioblastoma patients after chemoprotective HSC gene therapy,” Science Translational Medicine, vol. 4, no. 133, Article ID 133ra57, 2012.

[72]. M. G. Ott, M. Schmidt, K. Schwarzwaelder et al., “Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1,” Nature Medicine, vol. 12, no. 4, pp. 401–409, 2006.

[73]. S. Stein, M. G. Ott, S. Schultze-Strasser et al., “Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease,” Nature Medicine, vol. 16, no. 2, pp. 198–204, 2010.

[74]. J. Zhang, E. B. Tarbet, H. Toro, and D.-C. C. Tang, “Adenovirusvectored drug-vaccine duo as a potential driver for conferring mass protection against infectious diseases,” Expert Review of Vaccines, vol. 10, no. 11, pp. 1539–1552, 2011.

[76]. P. Lam, G. Khan, R. Stripecke et al., “The innovative evolution of cancer gene and cellular therapies,” Cancer Gene Therapy, vol. 20, no. 3, pp. 141–149, 2013.

[77]. A. Aiuti, L. Biasco, S. Scaramuzza et al., “Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome,” Science, vol. 341, no. 6148, Article ID 1233151, 2013.

[78]. N. P. Restifo, M. E. Dudley, and S. A. Rosenberg, “Adoptive immunotherapy for cancer: harnessing the T cell response,” Nature Reviews Immunology, vol. 12, no. 4, pp. 269–281, 2012.

[79]. M. H. Kershaw, J. A. Westwood, and P. K. Darcy, “Gene-engineered T cells for cancer therapy,” Nature Reviews Cancer, vol. 13, no. 8, pp. 525–541, 2013.

[80]. M. Danilo, M. Eusebio, P. C. Carla et al., “In vivo engineering of oncogenic chromosomal rearrangements with the CRISPR/Cas9 system,” Nature, vol. 516, no. 7531, pp. 423–427, 2014.

[81]. L. Jun, P. Shifeng, H. H. Mindy, and N. Nicholas, Targeting WntDriven Cancer through the Inhibition of Porcupine by LGK974, MRC Laboratory of Molecular Biology, Cambridge, UK, 2013.

[82]. J. H. C. M. Kreijtz, L. C. M. Wiersma, H. L. M. De Gruyter et al., “A single immunization with modified vaccinia virus Ankara-based influenza virus H7 vaccine affords protection in the influenza A(H7N9) pneumonia ferret model,” The Journal of Infectious Diseases, vol. 211, no. 5, pp. 791–800, 2015.

[83]. J. P. Hughes, G. Alusi, and Y. Wang, “Viral gene therapy for head and neck cancer,”The Journal of Laryngology & Otology, vol. 129, no. 4, pp. 314–320, 2015.

[84]. J. D. Smith, “Human Macrophage Genetic Engineering,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 36, no. 1, pp. 2–3, 2016.

[85]. E. St¨oger, C. Vaquero, E. Torres et al., “Cereal crops as viable production and storage systems for pharmaceutical scFv antibodies,” Plant Molecular Biology, vol. 42, no. 4, pp. 583–590, 2000.

[86]. C. Vaquero, M. Sack, F. Schuster et al., “A carcinoembryonic antigen-specific diabody produced in tobacco,” The FASEB journal, vol. 16, no. 3, pp. 408–410, 2002.

[87]. E. Karrer, S. H. Bass, R. Whalen, and P. A. Patten, U.S. Patent No. 8,252,727, 2012.

[88]. R. M. Ionescu, J. Vlasak, C. Price, and M. Kirchmeier, “Contribution of variable domains to the stability of humanized IgG1 monoclonal antibodies,” Journal of Pharmaceutical Sciences, vol. 97, no. 4, pp. 1414–1426, 2008.

[89]. C. W. Adams, D. E. Allison, K. Flagella et al., “Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab,” Cancer Immunology, Immunotherapy, vol. 55, no. 6, pp. 717–727, 2006.

[90]. A. A. McCormick, S. Reddy, S. J. Reinl et al., “Plant-produced idiotype vaccines for the treatment of non-Hodgkin’s lymphoma: safety and immunogenicity in a phase I clinical study,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 29, pp. 10131–10136, 2008.

[91]. M. Bendandi, S. Marillonnet, R. Kandzia et al., “Rapid, highyield production in plants of individualized idiotype vaccines for non-Hodgkin’s lymphoma,” Annals of Oncology, vol. 21, no. 12, pp. 2420–2427, 2010.

[92]. S. Kathuria, R. Sriraman, R. Nath et al., “Efficacy of plantproduced recombinant antibodies against HCG,” Human Reproduction, vol. 17, no. 8, pp. 2054–2061, 2002.

[93]. A. Rostami-Hodjegan and G. T. Tucker, “Simulation and prediction of in vivo drug metabolism in human populations from in vitro data,” Nature Reviews Drug Discovery, vol. 6, no. 2, pp. 140–148, 2007.

[94]. J. K. Nicholson, E. Holmes, and I. D. Wilson, “Gut microorganisms, mammalian metabolism and personalized health care,” Nature Reviews Microbiology, vol. 3, no. 5, pp. 431–438, 2005.

[95]. Q. R. Fan and W. A. Hendrickson, “Structure of human folliclestimulating hormone in complex with its receptor,” Nature, vol. 433, no. 7023, pp. 269–277, 2005.

[96]. M. Assidi, I. Dufort, A. Ali et al., “Identification of potential markers of oocyte competence expressed in bovine cumulus cells matured with follicle-stimulating hormone and/or phorbol myristate acetate in vitro,” Biology of Reproduction, vol. 79, no. 2, pp. 209–222, 2008.

[97]. Z.-B. Hu and M. Du, “Hairy root and its application in plant genetic engineering,” Journal of Integrative Plant Biology, vol. 48, no. 2, pp. 121–127, 2006.

[98]. C.-Q. Ling, L.-N. Wang, Y. Wang et al., “The roles of traditional Chinese medicine in gene therapy,” Journal of integrative medicine, vol. 12, no. 2, pp. 67–75, 2014.

[99]. L. Mazzoni, P. Perez-Lopez, F. Giampieri et al., “The genetic aspects of berries: from field to health,” Journal of the Science of Food and Agriculture, vol. 96, no. 2, pp. 365–371, 2016.

[100]. S. Ripp, D. E. Nivens, Y. Ahn et al., “Controlled field release of a bioluminescent genetically engineered microorganism for bioremediation process monitoring and control,” Environmental Science and Technology, vol. 34, no. 5, pp. 846–853, 2000.

[102]. G. S. Sayler, C. D. Cox, R. Burlage et al., “Field application of a genetically engineered microorganism for polycyclic aromatic hydrocarbon bioremediation process monitoring and control,” in Novel Approaches for Bioremediation of Organic Pollution, pp. 241–254, Springer, New York, NY, USA, 1999.

[103]. J. M. H. King, P. M. DiGrazia, B. Applegate et al., “Rapid, sensitive bioluminescent reporter technology for naphthalene exposure and biodegradation,” Science, vol. 249, no. 4970, pp. 778–781, 1990.

[104]. J. Chatterjee and E. A. Meighen, “Biotechnological applications of bacterial bioluminescence (lux) genes,” Photochemistry and Photobiology, vol. 62, no. 4, pp. 641–650, 1995.

[105]. K. Matsui, J. Togami, J. G. Mason, S. F. Chandler, and Y. Tanaka, “Enhancement of phosphate absorption by garden plants by genetic engineering: a new tool for phytoremediation,” BioMed Research International, vol. 2013, Article ID 182032, 7 pages, 2013.

[106]. R. B. Horsch, J. E. Fry, N. L. Hoffmann, D. Eichholtz, S. G. Rogers, and R. T. Fraley, “A simple and general method for transferring genes into plants,” Science, vol. 227, no. 4691, pp. 1229–1230, 1985.

[107]. M. Tamura, J. Togami, K. Ishiguro et al., “Regeneration of transformed verbena (verbena × hybrida) by Agrobacterium tumefaciens,” Plant Cell Reports, vol. 21, no. 5, pp. 459–466, 2003.

[108]. J. M. Jez, S. G. Lee, and A. M. Sherp, “The next green movement: plant biology for the environment and sustainability,” Science, vol. 353, no. 6305, pp. 1241–1244, 2016.

[109]. S. Clemens and J. F. Ma, “Toxic heavy metal and metalloid accumulation in crop plants and foods,” Annual Review of Plant Biology, vol. 67, no. 1, pp. 489–512, 2016.

[110]. E.-J. Kim, J.-H. Youn, C.-H. Park et al., “Oligomerization between BSU1 family members potentiates brassinosteroid signaling in Arabidopsis,” Molecular Plant, vol. 9, no. 1, pp. 178– 181, 2016.

[111]. D. Mani and C. Kumar, “Biotechnological advances in bioremediation of heavy metals contaminated ecosystems: an overview with special reference to phytoremediation,” International Journal of Environmental Science and Technology, vol. 11, no. 3, pp. 843–872, 2014.

[112]. M. W. Ullah, M. Ul-Islam, S. Khan, Y. Kim, and J. K. Park, “Structural and physico-mechanical characterization of biocellulose produced by a cell-free system,” Carbohydrate Polymers, vol. 136, pp. 908–916, 2016.

[113]. M. W. Ullah, M. Ul-Islam, S. Khan, Y. Kim, and J. K. Park, “Innovative production of bio-cellulose using a cell-free system derived from a single cell line,” Carbohydrate Polymers, vol. 132, pp. 286–294, 2015.

[114]. M.W. Ullah,W. A. Khattak, M. Ul-Islam, S. Khan, and J. K. Park, “Metabolic engineering of synthetic cell-free systems: strategies and applications,” Biochemical Engineering Journal, vol. 105, pp. 391–405, 2016.

[115]. A. Tiwari and A. Pandey, “Cyanobacterial hydrogen production—a step towards clean environment,” International Journal of Hydrogen Energy, vol. 37, no. 1, pp. 139–150, 2012.

[116]. P. Savakis and K. J. Hellingwerf, “Engineering cyanobacteria for direct biofuel production from CO2,” Current Opinion in Biotechnology, vol. 33, pp. 8–14, 2015.

[117]. C. Leang, N. S. Malvankar, A. E. Franks, K. P. Nevin, and D. R. Lovley, “Engineering Geobacter sulfurreducens to produce a highly cohesive conductive matrix with enhanced capacity for current production,” Energy and Environmental Science, vol. 6, pp. 1901–1908, 2013.

[118]. Z. Vajo, J. Fawcett, and W. C. Duckworth, “Recombinant DNA technology in the treatment of diabetes: insulin analogs,” Endocrine Reviews, vol. 22, no. 5, pp. 706–717, 2001.

[119]. J. M. DeJong, Y. Liu, A. P. Bollon et al., “Genetic engineering of taxol biosynthetic genes in Saccharomyces cerevisiae,” Biotechnology and Bioengineering, vol. 93, no. 2, pp. 212–224, 2006.

[120]. G. M. Walker, “Yeasts,” in Desk Encyclopedia of Microbiology, Elsevier, 2nd edition, 2009.

[121]. C. M´endez, G. Weitnauer, A. Bechthold, and J. A. Salas, “Structure alteration of polyketides by recombinant DNA technology in producer organisms prospects for the generation of novel pharmaceutical drugs,” Current Pharmaceutical Biotechnology, vol. 1, no. 4, pp. 355–395, 2000.

[122]. A. Misra, Challenges in Delivery of Therapeutic Genomics and Proteomics, Elsevier, Amsterdam, Netherlands, 2010.